Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In transgenic mouse model studies have shown that omega-3 fatty acid consumption can reduce Alzheimer disease risk. An examinations with Alzheimer patients DHA did not slow the rate of cognitive and functional decline of brain.

The Directive will enter into force on 9th Nov. 2010. Using animals should only be considered where a non-animal alternative is unavailable. To promote the principle of reduction, Member States should facilitate the establishment of programmes for sharing organs and tissues. Availability of alternative methods is dependent on the progress of the research into the development of alternatives. There is an increasing need for new methods to be developed and proposed for validation. Community programmes provide increasing funding for projects which aim to replace, reduce and refine the use of animals.

Harvard bioengineers have been awarded $3.3 million in funding from the National Institutes of Health and the U.S. Food and Drug Administration (NIH-FDA) to develop a "Heart-Lung Micromachine". The device will accelerate drug safety and efficacy testing.

The Congress Linz 2010, this year the major international scientific event in the field of the 3Rs, took place on 2nd – 4th September in Linz, Austria. The congress was held as a joint congress of the European Society for Toxicology In Vitro (ESTIV) and the European Society for Alternatives to Animal Testing (EUSAAT). It was therefore the 16th International Congress on In Vitro Toxicology, the 13th Annual Congress of EUSAAT and the 16th Congress on Alternatives to Animal Testing.